Search results for "DYAX"

REFINE RESULTS

SEARCH RESULTS

About 2 results. Sort By: Date | Relevance
UPDATE 3-BioCryst shares tumble after genetic disorder drug fails study

*Drug fails to beat placebo in mid-stage trial. Feb 8- BioCryst Pharmaceuticals Inc said its lead drug failed to reduce the frequency of recurrent swelling in patients with hereditary angioedema, sending its shares skidding as much as 68 percent in early trading on Monday. The results will clearly work in the favor of British drugmaker Shire Plc, which has two...
Source: Reuters
Shire, Baxalta combine into rare diseases leader

Shire clinched its six-month pursuit of Baxalta by agreeing to a $32 billion cash and stock offer.
Source: Reuters